{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:45:48Z","timestamp":1793090748190,"version":"4.5.0"},"reference-count":250,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1080\/1744666x.2019.1705785","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:56:41Z","timestamp":1576709801000},"page":"207-228","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":98,"title":["Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics"],"prefix":"10.1080","volume":"16","author":[{"given":"Ying-Ming","family":"Chiu","sequence":"first","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital","place":["Taichung, Taiwan"]},{"name":"College of Medicine, China Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology and Immunology Center, China Medical University Hospital","place":["Taichung, Taiwan"]},{"name":"College of Medicine, China Medical University","place":["Taichung, Taiwan"]},{"name":"Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital","place":["Taichung, Taiwan"]},{"name":"Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University","place":["Taichung, Taiwan"]},{"name":"Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm939"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket414"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.182"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148700"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1579642"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210713"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13243"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1607298"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu237"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.09.004"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1215245"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.047274"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.141846"},{"issue":"3","key":"e_1_3_5_20_1","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten AL","year":"2008","unstructured":"Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008 Mar;35(3):387\u2013393.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.16.9203"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.128637"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204960"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.025"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148783"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i3.344"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0113"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8909834"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0542-z"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4367-9"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.116"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1345722"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2571"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker190"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"e_1_3_5_36_1","first-page":"1","article-title":"Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis","volume":"22","author":"Sebastiani M","year":"2019","unstructured":"Sebastiani M, Milazzo L, Atzeni F, et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol. 2019;22:1\u20138.","journal-title":"Mod Rheumatol"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(03)00041-X"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.07.010"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3453"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3631-z"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.482"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21568"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem076"},{"issue":"3","key":"e_1_3_5_45_1","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten AL","year":"2008","unstructured":"Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387\u2013393.","journal-title":"J Rheumatol"},{"issue":"11","key":"e_1_3_5_46_1","first-page":"2201","article-title":"Leflunomide-associated infections in rheumatoid arthritis","volume":"34","author":"Jenks KA","year":"2007","unstructured":"Jenks KA, Stamp LK, O\u2019Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34(11):2201\u20132203.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23003"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)45:3<240::AID-ART255>3.0.CO;2-I"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep325"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201338"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1496-5"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.008"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.12.024"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22808"},{"key":"e_1_3_5_58_1","first-page":"2018:(8)","article-title":"Frequency of hospitalized infections is reduced in rheumatoid arthritis patients who received biological and targeted synthetic disease-modifying antirheumatic drugs after 2010","author":"Ichinose K","year":"2018","unstructured":"Ichinose K, Shimizu T, Umeda M, et al. Frequency of hospitalized infections is reduced in rheumatoid arthritis patients who received biological and targeted synthetic disease-modifying antirheumatic drugs after 2010. J Immunol Res. 2018;2018:(8).","journal-title":"J Immunol Res"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083188"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212825"},{"issue":"1","key":"e_1_3_5_61_1","first-page":"60","article-title":"Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage on rheumatic disease study of the Italian society for rheumatology","volume":"37","author":"Carrara G","year":"2019","unstructured":"Carrara G, Bortoluzzi A, Sakellariou G, et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage on rheumatic disease study of the Italian society for rheumatology. Clin Exp Rheumatol. 2019 Jan-Feb;37(1):60\u201366.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39399"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq343"},{"issue":"1","key":"e_1_3_5_66_1","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2018","unstructured":"Baraliakos X, Kivitz A, Deodhar A, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50\u201355.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"e_1_3_5_67_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp K","year":"2015","unstructured":"Papp K, Gottlieb A, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0193-2"},{"issue":"10","key":"e_1_3_5_69_1","first-page":"Abstract 2785","article-title":"Serious infections associated with tofacitinib in rheumatoid arthritis patients previously treated with methotrexate","volume":"69","author":"Machado M","year":"2017","unstructured":"Machado M, Moura CS, Guerra SF, et al., editors. Serious infections associated with tofacitinib in rheumatoid arthritis patients previously treated with methotrexate. Arthritis Rheumatol. 2017;69(S10):Abstract 2785","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1031743"},{"key":"e_1_3_5_71_1","unstructured":"Organization WH. Global tuberculosis report 2018. 2018. Geneva: World Health; 2019."},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00261402"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1405427"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24476"},{"issue":"7","key":"e_1_3_5_75_1","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona L","year":"2003","unstructured":"Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Jul;30(7):1436\u20131439.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1086\/506935"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206470"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.966"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21705"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0031"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23705"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153217"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix505"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213097"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2030-8"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu457"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00702.x"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.004"},{"issue":"3","key":"e_1_3_5_93_1","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian H","year":"2007","unstructured":"Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168\u2013173.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"e_1_3_5_94_1","first-page":"20","article-title":"Mechanism of action of leflunomide in rheumatoid arthritis","volume":"53","author":"Fox RI","year":"1998","unstructured":"Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl. 1998 Jul;53:20\u201326.","journal-title":"J Rheumatol Suppl"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056283"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0716-8"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3460"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.94"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90676-4"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072967"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.11.002"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1240783"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.008"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0283"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0406-3"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu185"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu172"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0368"},{"issue":"4","key":"e_1_3_5_114_1","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong SS","year":"2007","unstructured":"Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007 Apr;34(4):706\u2013711.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbr.2017.05.003"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12188"},{"key":"e_1_3_5_117_1","first-page":"43524","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence","author":"Kisacik B","year":"2016","unstructured":"Kisacik B, Pamuk ON, Onat AM, et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol. 2016;43(3):43524\u201343529.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3714-6"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200489"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1483238"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151092"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120906"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0243-4"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0583-8"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex238"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex443"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612872"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq368"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141288"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1123211"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes365"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1086\/587989"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4521"},{"issue":"5","key":"e_1_3_5_136_1","first-page":"893","article-title":"Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study","volume":"34","author":"Vassilopoulos D","year":"2016","unstructured":"Vassilopoulos D, Delicha EM, Settas L, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clin Exp Rheumatol. 2016 Sep-Oct;34(5):893\u2013900.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep36923"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1103733"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1676-y"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207319"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301073"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.216"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-1988-2"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-449"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01434.x"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2385-1"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127233"},{"issue":"1","key":"e_1_3_5_155_1","first-page":"93","article-title":"Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study","volume":"35","author":"Giannitti C","year":"2017","unstructured":"Giannitti C, Lopalco G, Vitale A, et al. Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. Clin Exp Rheumatol. 2017 Jan-Feb;35(1):93\u201397.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1419842"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.22461"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1996.tb00051.x"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9074-8"},{"issue":"8","key":"e_1_3_5_160_1","first-page":"983","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese L","year":"2006","unstructured":"Calabrese L, Zein N, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Br Med J. 2006;65(8):983.","journal-title":"Br Med J"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-5-381"},{"issue":"10","key":"e_1_3_5_163_1","first-page":"2037","article-title":"Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy","volume":"25","author":"Narvaez J","year":"1998","unstructured":"Narvaez J, Rodriguez-Moreno J, Martinez-Aguila M, et al. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol. 1998;25(10):2037.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q"},{"issue":"3","key":"e_1_3_5_165_1","first-page":"375","article-title":"Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Hagiyama H","year":"2004","unstructured":"Hagiyama H, Kubota T, Komano Y, et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22(3):375\u2013376.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"e_1_3_5_166_1","first-page":"227","article-title":"Hepatic safety of methotrexate in rheumatoid arthritis patients with hepatitis B surface antigen","volume":"8","author":"Park YW","year":"2001","unstructured":"Park YW, Park JH, Bae YS, et al. Hepatic safety of methotrexate in rheumatoid arthritis patients with hepatitis B surface antigen. J Korean Rheum Assoc. 2001;8(4):227\u2013235.","journal-title":"J Korean Rheum Assoc"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0367-5"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0521-9"},{"issue":"6","key":"e_1_3_5_169_1","first-page":"888","article-title":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate","volume":"25","author":"Gwak GY","year":"2007","unstructured":"Gwak GY, Koh K, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25(6):888\u2013889.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9597-6"},{"issue":"2","key":"e_1_3_5_171_1","first-page":"320","article-title":"Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with hepatitis B virus carriage and safety observation","volume":"31","author":"Ming-Xu H","year":"2015","unstructured":"Ming-Xu H, Chen M, Cai Y, et al. Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with hepatitis B virus carriage and safety observation. Pak J Med Sci. 2015;31(2):320\u2013324.","journal-title":"Pak J Med Sci"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.208413"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22905"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0337-z"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110289"},{"key":"e_1_3_5_176_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.4.2469-2476.2003"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182380a76"},{"key":"e_1_3_5_178_1","first-page":"1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF\u03b1 agents: a retrospective analysis of 49 cases","author":"Ryu HH","year":"2012","unstructured":"Ryu HH, Lee EY, Shin K, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNF\u03b1 agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:1\u20136.","journal-title":"Clin Rheumatol"},{"key":"e_1_3_5_179_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.5251"},{"key":"e_1_3_5_180_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20035"},{"issue":"1","key":"e_1_3_5_181_1","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee YH","year":"2012","unstructured":"Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2012 Jan-Feb;31(1):118\u2013121.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_182_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00937.x"},{"key":"e_1_3_5_183_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/926836"},{"key":"e_1_3_5_184_1","article-title":"Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review","author":"Chen Y-M","year":"2017","unstructured":"Chen Y-M, Yang -S-S, Chen D-Y. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review. J Microbiol Immunol Infect. 2017;52(1):1\u20138.","journal-title":"J Microbiol Immunol Infect"},{"key":"e_1_3_5_185_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7081"},{"key":"e_1_3_5_186_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202088"},{"key":"e_1_3_5_187_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151105"},{"issue":"5","key":"e_1_3_5_188_1","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien Y","year":"2017","unstructured":"Tien Y, Yen H, Chiu Y. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(5):831\u2013836.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"e_1_3_5_189_1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim PS","year":"2012","unstructured":"Kim PS, Ho GY, Prete PE, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken). 2012;64(8):1265\u20131268.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_3_5_190_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22786"},{"key":"e_1_3_5_191_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken384"},{"key":"e_1_3_5_192_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12359"},{"key":"e_1_3_5_193_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0458-z"},{"key":"e_1_3_5_194_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27716"},{"key":"e_1_3_5_195_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209973"},{"key":"e_1_3_5_196_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2989"},{"key":"e_1_3_5_197_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0671-z"},{"key":"e_1_3_5_198_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12461"},{"key":"e_1_3_5_199_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00457-3"},{"key":"e_1_3_5_200_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211322"},{"key":"e_1_3_5_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"e_1_3_5_202_1","unstructured":"Organization WH. Global hepatitis report 2017. World Health Organization; 2017."},{"key":"e_1_3_5_203_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.7.635"},{"key":"e_1_3_5_204_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22463"},{"key":"e_1_3_5_205_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160983"},{"key":"e_1_3_5_206_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.07.009"},{"issue":"3","key":"e_1_3_5_207_1","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok MY","year":"2000","unstructured":"Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000 May-Jun;18(3):363\u2013368.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_208_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.004"},{"key":"e_1_3_5_209_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370304"},{"key":"e_1_3_5_210_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11451"},{"key":"e_1_3_5_211_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep33104"},{"key":"e_1_3_5_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.004"},{"key":"e_1_3_5_213_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316650-000000000-00000"},{"key":"e_1_3_5_214_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.031"},{"key":"e_1_3_5_215_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S88306"},{"key":"e_1_3_5_216_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1423.058"},{"key":"e_1_3_5_217_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250233"},{"key":"e_1_3_5_218_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K"},{"key":"e_1_3_5_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.025"},{"issue":"2","key":"e_1_3_5_220_1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.028209","article-title":"Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection","volume":"63","author":"Calabrese LH","year":"2004","unstructured":"Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004 Nov;63(Suppl 2):ii18\u2013ii24.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_5_221_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.11.1078"},{"key":"e_1_3_5_222_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20702"},{"issue":"4","key":"e_1_3_5_223_1","first-page":"290","article-title":"Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities","volume":"17","author":"Vauloup C","year":"2006","unstructured":"Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw. 2006 Dec;17(4):290\u2013293.","journal-title":"Eur Cytokine Netw"},{"key":"e_1_3_5_224_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel123"},{"key":"e_1_3_5_225_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_3_5_226_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130658"},{"key":"e_1_3_5_227_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206711"},{"key":"e_1_3_5_228_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.05.002"},{"key":"e_1_3_5_229_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.05.013"},{"key":"e_1_3_5_230_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2378-0"},{"issue":"10","key":"e_1_3_5_231_1","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri C","year":"2008","unstructured":"Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008 Oct;35(10):1944\u20131949.","journal-title":"J Rheumatol"},{"key":"e_1_3_5_232_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1149-4"},{"key":"e_1_3_5_233_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2962-6"},{"key":"e_1_3_5_234_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/406901"},{"key":"e_1_3_5_235_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000536"},{"key":"e_1_3_5_236_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes051"},{"issue":"5","key":"e_1_3_5_237_1","first-page":"816","article-title":"Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection","volume":"31","author":"Giannitti C","year":"2013","unstructured":"Giannitti C, Fineschi I, Frediani B, et al. Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):816.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_5_238_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214400"},{"key":"e_1_3_5_239_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes246"},{"key":"e_1_3_5_240_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181f4cd92"},{"key":"e_1_3_5_241_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2017.17003"},{"key":"e_1_3_5_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.04.013"},{"key":"e_1_3_5_243_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34322"},{"key":"e_1_3_5_244_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21022"},{"key":"e_1_3_5_245_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40495"},{"key":"e_1_3_5_246_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1596-y"},{"key":"e_1_3_5_247_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2989"},{"key":"e_1_3_5_248_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2017-001212"},{"key":"e_1_3_5_249_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12045"},{"key":"e_1_3_5_250_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12461"},{"key":"e_1_3_5_251_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14301"},{"key":"e_1_3_5_252_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2019.1705785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:59:27Z","timestamp":1772711967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2019.1705785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":250,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1080\/1744666X.2019.1705785"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2019.1705785","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}